Navigation Links
Invida Selects LaVoie Group as Public Relations Agency of Record
Date:2/8/2010

LaVoie Group, a life science-focused strategic communications agency, announced today that it has been selected by Invida Group, the leading provider of healthcare brands and services in Asia Pacific, to develop and execute its corporate communications and public relations program.

Salem, MA (Vocus) February 8, 2010 -- LaVoie Group, a life science-focused strategic communications agency, announced today that it has been selected by Invida Group, the leading provider of healthcare brands and services in Asia Pacific, to develop and execute its corporate communications and public relations program. Singapore-based Invida has a presence in 13 countries in the Asia-Pacific region, and has selected LaVoie Group to build upon its corporate identity and brand awareness as the company moves into a phase of focused expansion in key growth regions such as China and India.

Donna L. LaVoie, President & CEO of LaVoie Group, commented, "Invida provides pharmaceutical and biotechnology partners proven brand and sales experience and track record in bringing their products to the three billion patients in the fastest growing region in the world – the Asia-Pacific region. We look forward to continuing our work with the Invida team to develop and execute a corporate communications program, designed to align with Invida’s business strategy and growth opportunities in these exciting markets.”

John A. Graham, Chief Executive Officer of Invida Group Pte Ltd, added, "We selected LaVoie Group for their experience working with leading life sciences corporate brands. As Invida expands throughout Asia Pacific and grows its presence in these key markets, LaVoie Group will help us in creating and executing a strong and cohesive strategy to further our message as we seek to continue working with top multi-national corporations to market and sell their product lines throughout the region.”

About Invida Group Pte Ltd.
Invida improves the lives of patients in Asia by commercializing differentiated pharmaceutical products of superior quality - the result of which will allow all our stakeholders to prosper. We do this through our proven brand marketing and sales know-how, strong expertise across a number of key therapeutic categories and deep experience in all critical Asian markets. Comprehensive functional capabilities provide rapid market access delivered by our passionate team of professionals.

With more than 4,000 employees in 13 countries in Asia Pacific, Invida operates across the commercial value chain from regulatory approval and product launch to lifecycle management. We manage a portfolio of proprietary healthcare brands, as well as licensed products from small biotech firms and large multinational companies. Partnering is a critical component of Invida’s business model. We collaborate closely with our partners in developing effective strategies and put our extensive experience behind maximizing the potential of the assets entrusted to us. For more information, please visit http://www.invida.com.

About LaVoie Group, Inc.
LaVoie Group provides senior-level counsel and tactical implementation of strategic communications programs designed to properly position, create visibility and drive value for each client. We help our life sciences companies attract capital, reach corporate partners, generate revenue and build their companies through integrated communications programs. In addition to Invida, our clients include emerging and leading global brands in the life science sector, such as Pfizer, sanofi-aventis, Vertex Pharmaceuticals, Genetix Pharmaceuticals, Rockwell Medical, Cardioxyl Pharmaceuticals, and Profectus Biosciences.

In 2009, LaVoie Group was selected for three industry awards including the coveted Impact Award for "Best Industry-Exclusive Agency," sponsored by the League of American Communications Professionals (LACP) and the Bell Ringer merit award for corporate identity by the New England Publicity Club. LaVoie Group is also ranked by O’Dwyer’s PR Report as one of the leading independent healthcare PR firms in the U.S. For more information, please visit http://www.lavoiegroup.com.

Contact:
Donna L. LaVoie
President & CEO
LaVoie Group
978-745-4200 X103
http://www.lavoiegroup.com

# # #

Read the full story at http://www.prweb.com/releases/Invida_Group/LaVoie_Group/prweb3573384.htm.


'/>"/>
Source: PRWeb
Copyright©2010 Vocus, Inc.
All rights reserved  

Related biology technology :

1. Biotech Company Ansaris Selects Surety for Integrity and Authenticity Protection of Its Lab Informatics Data
2. Japan Science and Technology Agency (JST) Selects Scopus Custom Data for Citation Linkage Analysis Between Scientific Articles and Patents
3. Molecular Genetics Core Facility at Childrens Hospital Boston Selects HybSelect from febit for Targeted Resequencing
4. Quintiles Selects invivodata as Primary Partner for ePRO Solutions; Collaboration to Enhance Value, Effectiveness and Speed in Drug Development
5. Leading Global CRO Selects iCardiac as Preferred Vendor
6. The Massachusetts Biotechnology Council Selects Social Media Marketing Agency 451 Marketing To Develop A Social Media Strategy For 2010
7. Joint BioEnergy Institute Selects Surety's AbsoluteProof to Protect the Integrity and Legally Defend the Authenticity of its Scientific Intellectual Property
8. WuXi PharmaTech Selects Labcyte POD(TM) 810 Platform for High-Throughput Screening
9. Another Top Five Pharmaceutical Company Selects iCardiac as Preferred Provider of ECG Core Lab Services
10. iSirona Selects New Chairman of the Board
11. Memorial Sloan-Kettering Selects Artemis as Affiliate for India
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Invida Selects LaVoie Group as Public Relations Agency of Record
(Date:10/12/2017)... ... October 12, 2017 , ... ... Rosalindâ„¢, the first-ever genomics analysis platform specifically designed for life science researchers ... honor of pioneering researcher Rosalind Franklin, who made a major contribution to ...
(Date:10/11/2017)... ... October 11, 2017 , ... The CRISPR-Cas9 ... enabling overexpression experiments and avoiding the use of exogenous expression plasmids. The simplicity ... for performing systematic gain-of-function studies. , This complement to loss-of-function studies, such ...
(Date:10/11/2017)... Alto, CA, USA (PRWEB) , ... October 11, 2017 , ... ... set to take place on 7th and 8th June 2018 in San Francisco, CA. ... policy influencers as well as several distinguished CEOs, board directors and government officials from ...
(Date:10/11/2017)... BioMarketing, a leading provider of patient support solutions, has announced ... network, which will launch this week. The VMS CNEs will ... to enhance the patient care experience by delivering peer-to-peer education ... professionals to help women who have been diagnosed and are ... ...
Breaking Biology Technology:
(Date:8/23/2017)... public,s help is being enlisted in what,s thought to be the biggest ... human body –and are believed to affect health.  ... The Microbiome Immunity Project is the largest study to date ... project's goal is to help advance scientific knowledge of the role of ... The ...
(Date:6/14/2017)... , June 15, 2017  IBM (NYSE: IBM ) ... international tech event dedicated to developing collaboration between startups and ... on June 15-17. During the event, nine startups will showcase ... value in various industries. France ... the international market, with a 30 percent increase in the ...
(Date:4/24/2017)... 24, 2017 Janice Kephart , ... Identity Strategy Partners, LLP (IdSP) , today issues ... President Trump,s March 6, 2017 Executive Order: ... vetting can be instilled with greater confidence, enabling ... all refugee applications are suspended by until at ...
Breaking Biology News(10 mins):